Fremont, CA-based Cytek Biosciences opened a new 50,000 ft2 facility in Wuxi, China. The facility offers the advantage of fostering unique vendor relationships and further facilitates Cytek to manufacture its own cell analysis product components, according to Wenbin Jiang, PhD, the company’s CEO.
In addition to bolstering Cytek’s manufacturing capabilities, the facility also accommodates Cytek Wuxi operations, research and development, marketing, human resources, and sales teams, added Jiang, who also pointed out that Cytek is the creator of the first commercialized fluorescence-based flow cytometry platform to achieve 40 colors.
“The increasing application of cellular analysis in various fields, including immuno-oncology, infectious diseases and immunology, has led to a rising need for advanced cell analysis solutions, and we are taking a proactive approach to accommodate it,” said Jiang. “Our roadmap has us continuing to expand our global footprint and continuing to give scientists the tools and support they need to advance their research.”
Cresset expands North American presence
Cambridge, U.K.-based Cresset, which provides in silico solutions for drug discovery, has expanded its existing North American presence with the creation of a new facility in the Cambridge Innovation Center (CIC) in the greater Boston area. The move marks a major milestone in the next phase of the company’s international expansion, says Rob Scoffin, DPhil, CEO, who notes that Cresset has grown into a drug discovery solutions company with a “genuine global reach, with more than 50% of its revenues now coming from outside the U.K.”
The CIC is already home to over 300 life science and biotech organizations, ranging from startups to accelerators, innovation arms of global pharmaceutical companies, and venture capitalists. The U.S. entity will enable Cresset to employ people directly in North America for the first time, bringing them closer to their customer base and expanding their relationships with the world-class scientific talent available in the Boston area, continues Scoffin.
Cresset will have a small team based in Boston, who will be able to host face-to-face meetings and customer workshops to spearhead the next phase of their North American expansion, according to Scoffin.
“Having such a highly skilled team in place in Boston will help enable greater integration between the U.K. and U.S. teams and provide opportunities to network with the local community. As part of this, we have committed to putting a director in Boston on a regular basis to cement our presence in the local pharma and life science community,” he explains.
“The centers of excellence in Cambridge and Boston are world-renowned and have become a focal point for investment and growth over the last 15 years. The office will enable us to offer more local support to our clients, which is in their time zone, and provide that crucial in-person contact for building relationships. Through the benefits of being part of the CIC building and other regional associations, we will be able to support our U.S. clients more effectively and enhance our existing service offering.”
